Sandbox Erice 8 - Revision history

Student at 12:44, 6 June 2010

Student — Sun, 06 Jun 2010 12:44:31 GMT

←Older revision		Revision as of 12:44, 6 June 2010
Line 1:		Line 1:
-	[[Image:3cl0_8.png]]	+	[[Image:3cl0_8.png\|thumb\|left\|150px\|influenza neuraminidase (3cl0)]]

	'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.		'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.

Student at 12:38, 6 June 2010

Student — Sun, 06 Jun 2010 12:38:55 GMT

←Older revision		Revision as of 12:38, 6 June 2010
Line 1:		Line 1:
	[[Image:3cl0_8.png]]		[[Image:3cl0_8.png]]
		+
	'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.		'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.

Student at 12:38, 6 June 2010

Student — Sun, 06 Jun 2010 12:38:35 GMT

←Older revision		Revision as of 12:38, 6 June 2010
Line 1:		Line 1:
		+	[[Image:3cl0_8.png]]
	'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.		'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.

Student at 12:29, 6 June 2010

Student — Sun, 06 Jun 2010 12:29:51 GMT

←Older revision		Revision as of 12:29, 6 June 2010
Line 4:		Line 4:
	<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />		<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />

-	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including <scene name='Sandbox_Erice_8/Zoom_3cl0/1'>oseltamivir</scene> (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.	+	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including <scene name='Sandbox_Erice_8/Zoom_3cl0/1'>oseltamivir</scene> (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (<scene name='Sandbox_Erice_8/Oseltamivir/1'>H274Y</scene>), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.

Student at 11:59, 6 June 2010

Student — Sun, 06 Jun 2010 11:59:07 GMT

←Older revision		Revision as of 11:59, 6 June 2010
Line 4:		Line 4:
	<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />		<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />

-	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.	+	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including <scene name='Sandbox_Erice_8/Zoom_3cl0/1'>oseltamivir</scene> (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.

Student at 11:49, 6 June 2010

Student — Sun, 06 Jun 2010 11:49:40 GMT

←Older revision		Revision as of 11:49, 6 June 2010
Line 2:		Line 2:

	== Exploring the Structure ==		== Exploring the Structure ==
		+	<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />

	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.		Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.
-
-	<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />

Student at 11:48, 6 June 2010

Student — Sun, 06 Jun 2010 11:48:47 GMT

←Older revision		Revision as of 11:48, 6 June 2010
Line 5:		Line 5:
	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.		Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.

-	<applet load='~~2hu4~~' size='300' frame='true' align='right' caption='Insert caption here' />	+	<applet load='3cl0' size='300' frame='true' align='right' caption='Insert caption here' />

Student at 11:47, 6 June 2010

Student — Sun, 06 Jun 2010 11:47:57 GMT

←Older revision		Revision as of 11:47, 6 June 2010
Line 4:		Line 4:

	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.		Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.
-	References

-	Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008 Jun 26;453(7199):1258-61. Epub 2008 May 14. PMID:18480754	+	<applet load='2hu4' size='300' frame='true' align='right' caption='Insert caption here' />

Student at 11:45, 6 June 2010

Student — Sun, 06 Jun 2010 11:45:34 GMT

←Older revision		Revision as of 11:45, 6 June 2010
Line 1:		Line 1:
-	Influenza neuraminidase is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.	+	'''Influenza neuraminidase''' is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.

	== Exploring the Structure ==		== Exploring the Structure ==

-		+	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry [[2hu4]]). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry [[3cl0]]). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.
-	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry 2hu4). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry 3cl0). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.	+
	References		References

	Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008 Jun 26;453(7199):1258-61. Epub 2008 May 14. PMID:18480754		Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008 Jun 26;453(7199):1258-61. Epub 2008 May 14. PMID:18480754

Student at 11:40, 6 June 2010

Student — Sun, 06 Jun 2010 11:40:43 GMT

←Older revision		Revision as of 11:40, 6 June 2010
Line 1:		Line 1:
	Influenza neuraminidase is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.		Influenza neuraminidase is a glycoprotein in the influenza virus membrane. Before an infected cell can release the virus into its surroundings to infect new cells, neuraminidase must cleave sialic acid from both virus and cellular glycoproteins. Neuraminidase is a homotetramer -- here we will examine only one monomer.
-	Exploring the Structure	+
		+	== Exploring the Structure ==
		+

	Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry 2hu4). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry 3cl0). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.		Because of its important role in virus infectivity, several anti-viral drugs have been designed to target neuraminidase, including oseltamivir (Tamiflu) and zanamivir (Relenza). Oseltamavir binding to neuraminidase moves glutamate 276 towards histidine 274, making more room for oseltamavir to bind tightly (PDB entry 2hu4). But, in a common mutant (H274Y), a larger tyrosine replaces the smaller histidine 274, preventing glutamate 276 from moving to make room for oseltamavir binding, resulting in weaker drug binding and thus resistance (PDB entry 3cl0). Luckily the H274Y neuraminidase mutant is still susceptible to zanamivir, which is smaller than oseltamavir.